LTAS
VIR icon

Linden Thomas Advisory Services’s Vir Biotechnology VIR Stock Holding History

Linden Thomas Advisory Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,032
Closed -$320K – 423
2023
Q2 		$320K Sell
13,032
-145
-1% -$3.64K 0.07% 320
2023
Q1 		$307K Buy
13,177
+821
+7% +$21K 0.08% 315
2022
Q4 		$313K Buy
+12,356
New +$303K 0.09% 304

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Linden Thomas Advisory Services's VIR Position: Q3 2023 in Review

Linden Thomas Advisory Services sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 13,032 shares — an estimated $320K sold.

Linden Thomas Advisory Services first reported a position in VIR in Q4 2022 and held it in 3 quarters. The position peaked at $320K in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Linden Thomas Advisory Services reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 13,032 Vir Biotechnology shares in Q3 2023, an estimated $320K.
  • Linden Thomas Advisory Services first reported a position in Vir Biotechnology in Q4 2022 and held it in 3 quarters.
  • Linden Thomas Advisory Services's Vir Biotechnology position peaked at $320K in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2023, filed 20 Oct 2023.